CCA
MYGN icon

Clearwater Capital Advisors’s Myriad Genetics MYGN Stock Holding History

Clearwater Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200
Closed -$6K – 424
2018
Q1 		$6K Buy
+200
New +$6.77K ﹤0.01% 522

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Clearwater Capital Advisors's MYGN Position: Q2 2018 in Review

Clearwater Capital Advisors sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 200 shares — an estimated $6K sold.

Clearwater Capital Advisors first reported a position in MYGN in Q1 2018 and held it in 1 quarter. The position peaked at $6K in Q1 2018. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

  • Clearwater Capital Advisors reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
  • Clearwater Capital Advisors sold 200 Myriad Genetics shares in Q2 2018, an estimated $6K.
  • Clearwater Capital Advisors first reported a position in Myriad Genetics in Q1 2018 and held it in 1 quarter.
  • Clearwater Capital Advisors's Myriad Genetics position peaked at $6K in Q1 2018.
  • 258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Clearwater Capital Advisors's 13F filing for Q2 2018, filed 16 Aug 2018.